Bridgeway Capital Management, LLC Rain Therapeutics Inc. Transaction History

Bridgeway Capital Management, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.84 - $1.22 $21,000 - $30,500	25,000 Added 44.25%	81,500 $97,000
Q3 2023 Nov 14, 2023	BUY	$0.82 - $1.42 $46,330 - $80,230	56,500 New	56,500 $48,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $101,010 - $162,110	13,000 New	13,000 $113,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.